Be sure to catch this pitch from an SF-based startup at our April 19 Startup Showcase! AESOP Technology is about “Deep Clinical Reasoning AI” to improve the clinical decision-making process, enhance medical coding quality, and prioritize patient safety. Its “Patient Safety-Centric Product Portfolio” boasts 99% accuracy in identifying and analyzing data and integrating directly into physicians' clinical workflows. The AI approach it developed, called “DeepDRG,” unlocks understanding of how diagnoses are typically associated with structured clinical data like lab results, medications, and procedures. It makes documentation easier, faster, and less error-prone using Machine Learning on 3.2 billion patient visits. AESOP was a Mayo Platform_Accelerate startup in Cohort 2. It is not currently raising, but planning to as soon as late 2024.
MinneAnalytics’ Post
More Relevant Posts
-
Artificial intelligence (AI) is rapidly transforming the healthcare industry, with AI-powered medical innovations playing an increasingly important role in diagnosis, treatment, and patient care. However, with this innovation comes a new set of regulatory hurdles. Join the University of Iowa Office of Innovation on Thursday, June 20th for the AI in Healthcare Symposium, where healthcare industry pioneers and national policy experts will delve into the challenges and opportunities presented by starting and scaling AI-powered healthcare startups. Learn more + register to attend: https://lnkd.in/gw5fSqr4
-
-
Fundraising & Business Development Expert | Digital Marketing Executive | Startup Consultant | Founder at DigitalMedHub | Secured over $10M in funding for high-impact healthcare startups.
🚀 Exciting Developments in AI-Driven Healthcare! 🚀 Wow!!!! X 3 😊 Atropos Health has just announced a $33 million Series B funding round, led by Valtruis with support from strategic investors like McKesson Ventures, Cencora Ventures, Sanofi Ventures, and the Merck Global Health Innovation Fund. This significant investment is set to propel their mission of democratizing access to high-quality, personalized real-world evidence. Their cutting-edge GENEVA OS platform, powered by generative AI, is transforming clinical data into actionable insights, which is crucial for advancing value-based care. With the new funds, Atropos Health aims to expand their Evidence Network, particularly in oncology and specialty care, and fully launch ChatRWD – an AI-driven tool that dramatically reduces the time needed to produce real-world evidence. The importance of real-world evidence in enhancing patient outcomes and driving efficient healthcare solutions cannot be overstated. This milestone underscores the potential of AI in healthcare, a field that I am deeply passionate about as an AI-driven healthcare startup consultant. #AI #Digitalmedhub #Healthcare #RealWorldEvidence #ValueBasedCare #GenerativeAI #AtroposHealth
-
🖋 Following the news of our recent investment in SmarterDx's $50 million Series B, we decided to put pen to paper to share our thoughts on what originally drew us to the company and team. We dig into the following topics: 🔹The Origin Story: Our early interest and belief in Michael Gao and Josh Geleris to bring the vision of SmarterDx to fruition. 🔹Sizing the Opportunity: Our perspectives on how AI can be leveraged to address inefficiencies in clinical documentation. 🔹SmarterDx's Solution: Why SmarterDx is uniquely positioned to tackle the AI clinical documentation problem and an update on the company's latest milestone wins. 🔹The Road Ahead: A glimpse into how the team is thinking about the future, looking towards new product launches that aim to broaden ROI. 🌟 You can read the full article here: https://lnkd.in/eJcjVy8U
Investing in SmarterDx
flarecapitalpartners.medium.com
-
Random & Stochastic: (Negotiator, Inventor, Entrepreneur, Researcher, Manager, Spiritualist, Soulist, Cosmologist, Scientologist, Effick-tologist, Wholysticist, Philosophaster, Transhumanist, Immortalist, etc. or ∞ loop)
Dear: Shareholders, Collaborators and Stakeholders: lablab.ai, New Native, GAIA AI Accelerator, WebShield NADPH Safety Net Connect, Milliman MedInsight ICON plc UBIX.AI Safe Health Compliant Minds In this spirit of lokahī—the Hawaiian principle of unity and harmony—I want to share what my team and I have been working on. We’ve uploaded a video and presentation of our emergent organizations, Immortiva & Life-Vault, envisioning the future of personalized health and longevity through a global collaborative effort: Immortiva and Life Vault initiative in LabLab AI: https://lnkd.in/eWudv7wX Presentation: https://lnkd.in/euA5fqdV) First Video: https://lnkd.in/ecPc8zfT Second Video: https://lnkd.in/e8tdvzZj Our proposal includes not just solving healthcare and aging challenges but also tackling systemic issues like the accessibility of intellectual property protections. Currently, the patent system, as structured, poses significant barriers for small entrepreneurs and inventors. Ideas made public in hackathons can lose their eligibility for patents—an issue disproportionately impacting those of us without the deep pockets of big-tech corporations. To address this, we propose that hackathon prizes be partially reinvested into covering provisional patent filing costs for ideas that are organized, improved, and patentable. You can explore the cost breakdown here: https://lnkd.in/eCyvNiXA On a personal note, the U.S. government: U.S. Department of Homeland Security The White House U.S. Customs and Border Protection Federal Reserve Bank of San Francisco Bureau of the Fiscal Service (Hawaii still being part of U.S.) owes me at least $3,715, which I would gladly dedicate to supporting patent-related expenses for the LabLab AI community—this hackathon and beyond. Additionally, I offer to mentor and brainstorm on provisional patents, sharing my humble, empirical knowledge on software and business method patents.USPTO World Intellectual Property Organization – WIPO Superintendencia de Industria y Comercio Let us unite under the banner of lokahī, striving for a world where collaboration and innovation thrive. Together, we can propose systemic changes to make intellectual property protection more inclusive and equitable. To the hackathon organizers and sponsors, mahalo for fostering such an incredible platform for innovation. Your support in user research and prototyping has been invaluable. Wishing everyone a Mele Kalikimaka, a prosperous new year, an incredible century, and a boundless millennium. As a transhumanist and immortalist, I believe our work today can echo far into the future of humanity, building pathways not only for extended life but for eternal harmony. With gratitude and hope, Another humble server at your service and the service of humanity https://lnkd.in/eyUBXBSm
LifeVault AI Powered Medical Histories
lablab.ai
-
ICYMI like I did, here's a summary of HLTH by Fierce Healthcare: https://lnkd.in/gKpiyXXk Adopting innovations such as AI tools in healthcare requires trust, accuracy, and reliability. But for startups, getting research, case studies, and results published can be a big hurdle. What are other things you think could move the needle?
HLTH 2024 recap: 5 notable trends spotted by reporters and key takeaways from executives
fiercehealthcare.com
-
🚀 AI Clinical Trial Planning and Site Selection 🌟 We're thrilled to announce the launch of Protocol SmartDesign and Investigator SmartSelect — two cutting-edge additions to our Citeline SmartSolutions suite, designed to accelerate the journey from pipeline to patient. These tools, powered by AI 🤖 and machine learning, bring unprecedented predictability and efficiency to clinical trial design and execution. Here's how they transform clinical research: 🔹 Protocol SmartDesign: Leverages Citeline’s industry-leading data 📊 to help researchers make informed decisions, forecast enrollment rates 📈, and streamline protocol development 📝. 🔹 Investigator SmartSelect: Revolutionizes country 🌍 and investigator selection by generating protocol-specific investigator pools in minutes ⏱️, optimizing site allocations, and ensuring trials are delivered on time ⏳. Both tools are built to reduce costly protocol amendments 💸, which can save sponsors hundreds of thousands of dollars and months of time ⏳. By harnessing the power of our robust data and AI, we're making clinical trials more efficient, predictable, and successful 🎯. These innovations align perfectly with Norstella’s mission to smooth the path to life-saving therapies 💊 for patients and providers, driving better outcomes across the board 🩺. Want to learn more? Visit us at Citeline.com or contact me directly. #LifeSciences #ClinicalTrials #AI #Innovation #Healthcare #PatientCare #ClinicalTrialDevelopment #ChiefMedicalOfficer #Citeline #Technology
-
-
Tempus AI Makes Successful Public Debut 🚀 Tempus AI, a leader in applying #artificialintelligence to healthcare, had a strong start as a publicly traded company yesterday. The medical data firm raised $410.7 million in its initial public offering, selling 23.4 million shares at $17.50 each. The shares opened at $24.25 and closed their first trading day at $27.94, up 59.7% from the IPO price, valuing the company at around $5 billion. Tempus was founded in 2015 by Eric Lefkofsky, a serial entrepreneur and co-founder of Groupon. The company has built a large library of molecular and clinical data, which it uses to develop AI-powered tools and insights to enable more personalized treatment decisions for cancer patients. With this successful IPO, Tempus is well capitalized to continue expanding its data platform, advancing its AI solutions, and partnering with healthcare providers to drive precision medicine forward. Congratulations to the entire Tempus AI team on this milestone! The future of data-driven, AI-enabled healthcare is bright.
Medical Data Firm Tempus AI Rises After $410.7 Million IPO
bloomberg.com
-
Providing the best Talent and Services for your team globally within the Life Science / Biotech sector
🚀 Major IPO News in Health Tech! 🚀 Tempus AI has priced its initial public offering (IPO) at $410.7M! 🎉💰 This significant milestone highlights the company's rapid growth and its pivotal role in integrating AI with healthcare. 🌟🧬 Tempus AI’s innovative approach leverages artificial intelligence to transform clinical data into actionable insights, driving advancements in personalised medicine and improving patient outcomes. 🩺💡 Excited to see the impact Tempus AI will continue to make in the healthcare sector! #HealthTech #IPO #ArtificialIntelligence #TempusAI #HealthcareInnovation #PersonalizedMedicine #Biotech #MedicalAdvancements #ClinicalData #InnovationInHealthcare #AIinHealthcare
-
Magnetic Ventures portfolio company, Paradigm was founded to use technology to change the status quo of how we conduct clinical trials - and they are doing just that through the use of disruptive technology, including generative AI. Paradigm recently worked with OpenAI to evaluate #GPT4 to reduce the administrative burden of screening patients for clinical trials. The results achieved were quite stunning, exceeding accuracy of industry best practice while dramatically decreasing the time to read, extract, and interpret medical record data. By incorporating LLMs into Paradigm’s platform, they can screen every patient faster, more accurately, and at a dramatically lower cost, helping create equitable access for any patient, anywhere. This is one more example of the impact technology is having across the healthcare ecosystem, and an example of Magnetic's founding investment thesis - that the future of healthcare is technology driven - at work. Congratulations to Paradigm and OpenAI team. #healthequity #clinicaltrials #deeptech #convergence #AI #healthcareinnovation #chatgpt4 #generativeai #generativeartificialintelligence
Paradigm was founded to change the status quo of how as an industry we conduct clinical trials - to focus on creating a more equitable model, where any patient, anywhere, can have access to best possible care including clinical trials as a routine care option. The current clinical development model is broken - it costs far too much, takes far too long to bring lifesaving drugs to market, and includes far too few patients of a diverse background. To be revolutionary and change both how we think of the clinical trial ecosystem and its intersection with healthcare, we realized we needed to have partners who were equally revolutionary in their approach. We can no longer accept minimal progress and incremental gains - clinical trials and drug development need a punctuated equilibrium moment. Paradigm is building a new model, from the ground up, using technology to scale access for clinical trials. Recently, we worked with OpenAI to evaluate #GPT4 to reduce the administrative burden of screening patients for clinical trials. Our team achieved amazing results, exceeding accuracy of industry best practice while dramatically decreasing the time to read, extract, and interpret medical record data. By incorporating LLMs into Paradigm’s platform, we can screen every patient faster, more accurately, and at a dramatically lower cost, helping create equitable access for any patient, anywhere. I am excited that OpenAI shared our results here: https://lnkd.in/gxAkmmGP. I want to thank the entire OpenAI team and the Paradigm team for this fantastic work!
OpenAI customer story: Paradigm
openai.com
-
A recent DIA Global Forum article highlighted critical gaps between sites, CROs, and sponsors. Clinials is exploring how technology can mitigate them. Let's dive into one core issue, budget/negotiations, and explore how AI can bridge divides. Key Issues Identified: -Time-consuming negotiations over budget items -Lack of fair compensation for all site activities -Transparency of accrual costs These challenges lead to inefficiencies, frustrations, and delays in clinical trials. But there's hope on the horizon. 💡 At Clinials, we've developed an AI solution to address these pain points: -Extract the Schedule of Activities (SoA) that a site needs to perform across multiple timepoints -Understand, and budget for, the clinical activities and medical devices required -Make quick and informed decisions Our AI-driven approach aims to: -Streamline budget negotiations -Present a transparent, systematic activity breakdown -Expedited decision-making -Give a better understanding of the work effort for each clinical trial By leveraging technology to tackle the core misalignments, we can create a more efficient, fair, and effective clinical research ecosystem. The DIA Global Forum article emphasizes the need for change. With AI solutions, we're poised to transform clinical trial management, fostering better understanding and collaboration between sites, CROs, and sponsors. What are your thoughts on using AI to address these industry challenges? Let's discuss how we can collectively improve the clinical trial landscape. #ClinicalTrials #DIAGlobalForum #AIinHealthcare #ClinicalResearch
-
